Shares of CRISPR Therapeutics (NASDAQ: CRSP) fell nearly 11% today after the company announced a share offering to boost its cash balance as it embarks on its first clinical trials. The gene editing pioneer will offer up to 4.84 million shares of common stock at $47.50 apiece. That could bring in gross proceeds of more than $230 million, albeit at the cost of increasing the number of shares outstanding by approximately 10%.
Continue Reading Below
While investors know that CRISPR Therapeutics exited the first half of 2018 with $320 million in cash and cash equivalents -- the second-highest tally among the three major CRISPR stocks -- the share offering is a smart move for multiple reasons.
As of 3:30 p.m. EDT on Friday, the stock had settled to a 9.2% loss.
Why is the share offering a positive development? For starters, clinical trials are expensive. CRISPR Therapeutics and partner Vertex Pharmaceuticals recently began the first-ever U.S.-based clinical trials for a CRISPR gene editing therapeutic. The pipeline's lead drug candidate, CTX001, is being evaluated as a potential treatment for the blood disorder beta thalassemia. It's also expected to enter clinical trials weighing its potential against sickle cell anemia before the end of 2018.
Additionally, given the high stakes of CRISPR gene editing technology (peer Editas Medicine hopes to one day develop a similar treatment against the same blood disorders), capital will be key to advancing trials and addressing any potential shortfalls as quickly as possible.
It's also worth noting that the share offering is well timed. As of Thursday's market close, CRISPR Therapeutics stock had soared over 100% since the beginning of the year. In other words, the company would have needed to offer twice as many shares to raise the same amount of cash if it pulled the trigger on Jan. 1. It's wise to take advantage of its premium market value.
Today's drop in share price is nothing for investors to panic over. Mr. Market is simply adjusting the stock price to account for the roughly 10% dilution of common stock, but CRISPR Therapeutics will have roughly the same market cap as it did the day before. Plus, it now has ample cash on hand to advance its lead drug candidate in trials around the world, and begin working on graduating its next clinic-ready assets from pre-clinical studies.
10 stocks we like better than CRISPR TherapeuticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and CRISPR Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of CRISPR Therapeutics. The Motley Fool recommends Editas Medicine and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.